Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Holiday Inn Amsterdam - Arena Towers

Nov 06, 2019 8:00 AM - Nov 07, 2019 4:30 PM

Hoogoorddreef 66a, 1101 BE Amsterdam, Netherlands

Global Forum for Qualified Persons for Pharmacovigilance (QPPV)

Networking your path to success amongst a World-class community

Back to Agenda

Session 1: Future of Pharmacovigilance – Impact of Globalisation

Session Chair(s)

Doris Irene Stenver, MD, MPA

Doris Irene Stenver, MD, MPA

Independent Pharmacovigilance Adviser

Unique Advice, Denmark

In this session key EU regulators will provide an update of current activities at the level of EMA and PRAC, 8 months after re-location to the Netherlands and 7 years after the creation of the PRAC. How far is EMA with regard to regaining the momentum in further developing pharmacovigilance, after years with need for strict prioritization to safeguard the core business? How does increasing globalization impact the Agency´s strategies? Which are the major achievements of the PRAC? And how does the future look like in a PRAC perspective? This session will also include an update on the WHO Pharmacovigilance System and activities to strengthen pharmacovigilance in low and middle income countries, linkages with the WHO global benchmarking activities and institutional development plans for regulatory agencies.

Speaker(s)

Peter Richard Arlett, MD, FFPM, FRCP

Data and Evidence to Support Benefit Risk Decisions

Peter Richard Arlett, MD, FFPM, FRCP

European Medicines Agency, Netherlands

Head Data Analytics and Methods Task Force

Sabine Straus, MD, PhD, MSc

Future of PRAC

Sabine Straus, MD, PhD, MSc

Medicines Evaluation Board (MEB), Netherlands

PRAC Chair, Staff Member

Shanthi Pal, DrSc, MPharm

Pharmacovigilance Systems Strengthening – WHO Perspective

Shanthi Pal, DrSc, MPharm

WHO, Switzerland

Group Lead, Medicines Safety, Safety & Vigilance

Have an account?